Pulmonology

ILD

Questions discussed in this category

How do you approach PJP prophylaxis in patients with rheumatic disease on corticosteroids?

Does the presence of ILD change your approach?

In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?

1 Answer available

Have you noticed poor response to Tyvaso DPI compared to the nebulized form in PH-ILD?

Could the intrinsic inspiratory capacity and distribution of medication be different between the two routes?

1 Answer available

Would you initiate antifibrotic therapy in a patient with CTD-ILD experiencing worsening symptoms and declining lung function, despite no clear evidence of fibrosis on CT scans?

CT changes are subsolid and ground glass nodules.

1 Answer available

Do you consider administration of nintedanib or pirfenidone via enteral tube in patients unable to take PO due to recurrent aspiration?

1 Answer available

What protective post-op measures do you recommend for a patient with scleroderma and a history of ILD, PH, Raynaud’s and digital ischemia undergoing cardiothoracic surgery?

1 Answer available

Is it safe to combine mycophenolate and adalimumab for management of pulmonary sarcoidosis in a patient that could not tolerate methotrexate?

3 Answers available

What is your approach to steroid sparing therapy in patients with suspected CTD-ILD?

2 Answers available

What is the risk of ILD recurrence in MDA5/Ro52 positive dermatomyositis following a lung transplantation?

2 Answers available

Do you screen for interstitial lung disease in patients with newly diagnosed polymyositis or dermatomyositis in the absence of respiratory symptoms?

3 Answers available

What dose and duration of steroid therapy do you use in steroid responsive ILD?

1 Answer available

Does your approach to the management of a patient with an acute exacerbation of CPFE where the ILD is attributed to IPF differ from the management of a patient with an exacerbation of IPF alone?

1 Answer available

Do you prescribe antifibrotics to patients with combined pulmonary fibrosis and emphysema (CPFE)?

1 Answer available

How would you manage subclinical ILD associated with MDA-5 Dermatomyositis?

Any indications for triple therapy in the patients with subclinical ILD associated with MDA-5 dermatomyositis?

1 Answer available

Papers discussed in this category

J Heart Lung Transplant, 2021 Nov

Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.

Interact Cardiovasc Thorac Surg, 2015 Jan 07

Recurrent polymyositis-associated lung disease after lung transplantation.

Rheumatology (Oxford, England), 2011 Dec 30

Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission.

Annals of the rheumatic diseases, 2022 Nov 03

2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases.

Frontiers in immunology, 2021 Apr 12

Using Routine Laboratory Markers and Immunological Indicators for Predicting Pneumonia in Immunocompromised Patients.

N Engl J Med, 2019 Sep 29

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Eur Respir J, 2019 Apr 18

Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials.

The Lancet. Respiratory medicine, 2016-09

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Respirology, 2013 Nov 29

Rituximab in severe, treatment-refractory interstitial lung disease.

Respir Res, 2022 Jun 21

Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis.

Arthritis & rheumatology (Hoboken, N.J.), 2015-05

Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.

International journal of rheumatic diseases, 2014-02

Neurosarcoidosis mimicking multiple sclerosis successfully treated with methotrexate and adalimumab.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2014-04-18

Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.

Clinical nuclear medicine, 2016-05

FDG PET/CT Evidence of Effective Treatment of Cardiac Sarcoidosis With Adalimumab.

J Investig Med High Impact Case Rep, 2021 Jan-Dec

Pituitary Sarcoidosis in a Pediatric Patient Successfully Treated With Adalimumab and Methotrexate.

Clinical therapeutics, 2018 Feb

Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.

N. Engl. J. Med., 2019 May 20

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Rheumatology (Oxford),

The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity.

Rheumatology (Oxford, England), 2023 Dec 01

Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature.

Pulmonology

ILD

Questions discussed in this category

Papers discussed in this category

Related Topics in Pulmonology